About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

BOSTON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the U.S. Department of Defense (DoD) has awarded a research grant to study the use of intranasal anti-CD3 therapy in traumatic spinal cord injury (SCI). This funding builds on Tiziana’s strategy t ...

BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its Chief Executive Officer, Ivor Elrifi, has purchased 193,848 shares of Tiziana common stock at a price of $1.65 per share in the open market. About Foralumab Foralumab, a fully human anti-CD3 m ...

Core Insights - Tiziana Life Sciences has initiated a Phase 2a clinical trial for intranasal foralumab in patients with Multiple System Atrophy (MSA), marking a significant step in developing therapies for this rare neurodegenerative disorder [1][3]. Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies using alternative drug delivery technologies, particularly through nasal administration [9]. - The company’s lead candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development, demonstrating a favorable safety profile and clinical response in prior studies [9][7]. Clinical Trial Details - The Phase 2a trial will evaluate the efficacy of foralumab in reducing neuroinflammation and aims to determine its potential to slow disease progression and improve quality of life for MSA patients [3][4]. - The trial involves a six-month open-label study with participants receiving treatment over eight dosing cycles [3]. Disease Context - Multiple System Atrophy is a rare and rapidly progressive neurodegenerative disorder affecting an estimated 15,000–50,000 individuals in the U.S., with no FDA-approved treatments available to alter its course [2][5]. - The disease leads to severe movement, balance, and autonomic function issues, with most patients surviving only 6–9 years post-diagnosis [5]. Mechanism of Action - Foralumab works by stimulating T regulatory cells through a novel, non-systemic delivery approach, targeting the immune processes that may drive neurodegeneration [4][6]. - Early studies have indicated potential benefits of foralumab in stabilizing or improving function in other neuroinflammatory conditions, such as multiple sclerosis [4][6].

Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world's key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. About this content About Emily Jarvie Emily began her career as a political journalis ...

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, is pleased to announce that the U.S. Food & Drug Administration (FDA) have approved the IND for its Phase 2a clinical trial of intranasal foralumab in patients with Multiple System Atrophy (MSA). Multiple System Atro ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Core Insights - Tiziana Life Sciences announced significant immunologic findings from the treatment of a moderate Alzheimer's Disease patient with intranasal foralumab, indicating its potential as a breakthrough therapy [1][5] Immunologic Findings - Transcriptional analysis of white blood cells before and after foralumab therapy showed profound immune modulatory effects, with significant changes in CD4 cells, CD8 cells, and monocytes, linking immune effects to reduced brain inflammation [2] - An unexpected increase in phagocytosis markers in classical monocytes suggests that nasal foralumab may enhance the clearance of amyloid plaques, potentially opening new treatment avenues for Alzheimer's Disease [3] Expert Commentary - Dr. Howard Weiner highlighted the promising reduction in microglial inflammation and unique immune changes observed in the treated Alzheimer's patient, indicating a step forward in understanding foralumab's therapeutic role in neuroinflammatory diseases [4] - Ivor Elrifi, CEO of Tiziana, emphasized the dual benefits of nasal foralumab in reducing brain inflammation and influencing amyloid pathology, with the treatment being well tolerated and continued by the patient [4] Company Commitment - The findings represent a significant milestone in developing novel therapies for Alzheimer's Disease, underscoring Tiziana Life Sciences' commitment to advancing transformative treatments for neurodegenerative disorders [5] About Foralumab - Foralumab is a fully human anti-CD3 monoclonal antibody that stimulates T regulatory cells when dosed intranasally, with ongoing studies showing improvements or stability in patients with Non-Active Secondary Progressive Multiple Sclerosis [6][7] - It is the only fully human anti-CD3 monoclonal antibody currently in clinical development, representing a novel approach for treating neuroinflammatory and neurodegenerative diseases [7] Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies, with intranasal foralumab demonstrating a favorable safety profile and clinical response in studies [8][9]

Group 1 - The article discusses Tiziana Life Sciences (NASDAQ: TLSA) and its ongoing drug development efforts, particularly focusing on the Foralumab drug and its additional Expanded Access Program (EAP) enrollment [2] - The author is affiliated with Biotech Analysis Central, which provides extensive analysis and resources for healthcare investors, including a library of over 600 biotech investing articles and a model portfolio of small and mid-cap stocks [2] - The service offered by Biotech Analysis Central is priced at $49 per month, with a yearly plan available at a discounted rate of $399, representing a 33.50% discount [1] Group 2 - The article does not provide specific financial data or performance metrics related to Tiziana Life Sciences or its products [4] - There are no disclosed positions or plans to initiate positions in the companies mentioned, indicating a neutral stance from the author [3]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive focuses on sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Group 2 - Proactive is a forward-looking company that adopts technology enthusiastically, utilizing decades of expertise and experience [4] - The company employs automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]